

УДК: 159.9

DOI: <https://doi.org/10.17816/nb117637>

## Чему эпидемия COVID-19 научила психиатров?

В.Д. Менделевич<sup>1</sup>, Ф.Ф. Гатин<sup>2</sup>, Р.Р. Хамитов<sup>1</sup><sup>1</sup>Казанский государственный медицинский университет, Казань, Россия<sup>2</sup>Казанская государственная медицинская академия — филиал Российской медицинской академии непрерывного профессионального образования, Казань, Россия*Автор, ответственный за переписку:* Владимир Давыдович Менделевич, [mendelevich\\_vl@mail.ru](mailto:mendelevich_vl@mail.ru)

### **АННОТАЦИЯ**

Статья посвящена анализу психопатологических последствий эпидемии COVID-19. Особо подчеркнут факт повышенной летальности от COVID-19 больных шизофренией и аффективными расстройствами. Сделан вывод о том, что на это повлияло нерациональное использование антипсихотиков, способствовавших появлению у пациентов сахарного диабета и избыточной массы тела.

**Ключевые слова:** COVID-19, шизофрения, психические расстройства, психофармакотерапия, рациональное использование антипсихотиков и антидепрессантов.

### **Для цитирования:**

Менделевич В.Д., Гатин Ф.Ф., Хамитов Р.Р. Чему эпидемия COVID-19 научила психиатров? // Неврологический вестник. 2022. Т. LIV. Вып. 4. С. 5–13. DOI: <https://doi.org/10.17816/nb117637>.

DOI: <https://doi.org/10.17816/nb117637>

## What did the COVID-19 epidemic learn psychiatrists?

Vladimir D. Mendelevich<sup>1</sup>, Foat F. Gatin<sup>2</sup>, Rustem R. Khamitov<sup>1</sup>

<sup>1</sup>Kazan State Medical University, Kazan, Russia

<sup>2</sup>Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia

*Corresponding author:* Vladimir D. Mendelevich, [mendelevich\\_vl@mail.ru](mailto:mendelevich_vl@mail.ru)

### **ABSTRACT**

The article is devoted to the analysis of the psychopathological consequences of the COVID-19 epidemic. Particular emphasis is placed on assessing the fact of increased mortality from COVID-19 in patients with schizophrenia and affective disorders. It is concluded that this was influenced by the irrational use of antipsychotics, which contributed to the appearance of diabetes and overweight in patients.

**Keywords:** COVID-19, schizophrenia, mental disorders, psychopharmacotherapy, rational use of antipsychotics and antidepressants.

### **For citation:**

Mendelevich VD, Gatin FF, Khamitov RR. What did the COVID-19 epidemic learn psychiatrists? *Neurology Bulletin*. 2022;LIV(4):5–13. DOI: <https://doi.org/10.17816/nb117637>.

---

Received: 16.12.2022

Accepted: 19.12.2022

Published: 26.01.2023


---

©Eco-Vector, 2022

The acute period of the COVID-19 pandemic demonstrated that, in addition to serious somatic (pulmonological, cardiovascular, etc.) complications and an attendant high mortality rate, the increased incidence of mental and behavioral disorders has become a significant problem [1–10]. Anxiety disorders, delirium, and insomnia are the conditions most frequently tracked. At the late stages of the new coronavirus infection, asthenia, increased fatigue, and cognitive impairment were detected [1, 4, 11–14]. Furthermore, the incidence of increased manifestations, failures of remission, and exacerbations were registered in patients who previously had psychopathologies, such as schizophrenia, bipolar affective disorder, and neurotic and organic mental disorders [7, 15–19].

that the related prevalence has been somewhat uneven across regions of the world.

Many of the short-term and long-term psychopathological effects of COVID-19 could be predicted based on the already-known patterns of transformation of mental functions during periods of viral infections. In particular, the development of so-called exogenous mental reactions in the form of asthenia, delirium, and cognitive impairment was already expected. It was not surprising that 9 months after the ingress of infection, one-fifth of patients (19%) continued to have these symptoms. Factors such as being of the female gender, at a younger age, medical history, depression, and the number of acute symptoms of COVID-19 have been seen to be associated with increased fatigue (Fig. 1) [12].



**Fig. 1.** Persistence of clinically significant fatigue and cognitive impairment 9 months after COVID-19 [12].

Following the acute period of the pandemic, the statistics indicated a significant increase (by 25.6%) in the prevalence of anxiety disorders across the world among 76.2 million people. The number of patients with a major depressive disorder increased from 38.7 to 49.4 million [20]. The largest growth (by 38.7%) was recorded in the Americas and South Africa, while in the Russian Federation, the increase was over 25%. During the pandemic, studies were conducted that have shown a risk of developing Alzheimer’s disease and other forms of dementia in people who have had COVID-19 [13, 21].

The work “Long-Term Mental Health Consequences of COVID-19: a Systematic Review” [20] summarized the data on the impact of a novel coronavirus infection on mental health and concluded

However, psychiatrists found some unexpected effects that needed to be analyzed. It seemed logical to seek clear evidence that patients infected with SARS-CoV-2 might develop a significant cognitive impairment [standardized mean difference  $-0.41$  (95% confidence interval  $-0.55; -0.27$ )], regardless of the stage of pathology and the age of the patients. However, another factor turned out to be unpredictable, as there was no clear relationship between the severity of the infection and the resultant degree of neurocognitive deficit [13].

The evidence that, in psychiatric patients, COVID-19 was much more severe, and had more pronounced negative consequences, also turned out to be scientifically perplexing. The prevalence of schizophrenia among 7,341 Korean patients with

**Table 1.** The mortality rate resulting from COVID-19 among mentally ill patients and in the group without mental disorders [24]

SARS-Cov-2-positive	Mortality rate, n (%)
All patients (n = 7003)	822 (11.7)
Schizophrenia spectrum disorders (n = 46)	12 (26.1)
Mood disorders (n = 374)	80 (21.4)
Anxiety disorders (n = 234)	29 (12.4)

COVID-19 was shown to be 3.6%, which increased the historic national prevalence rate for schizophrenia in Korea by more than five times (0.66%). The prevalence of schizophrenia in the case of severe COVID-19 was even higher, amounting to 5.4% [22]. Among 50,750 patients hospitalized with COVID-19 in France, the prevalence of schizophrenia was 1.6%, which was 60% higher than in the general population [16]. In addition, the presence of schizophrenia was found to be the second-largest risk factor for death from COVID-19 [23] and COVID-19 infection had a significant impact on the ultimate recovery and psychological well-being of patients with schizophrenia.

The comparative data on mortality deriving from a new coronavirus infection in patients with various mental disorders turned out to be even more shocking. The mortality rate was more than two times higher in the group of patients with schizophrenia, and almost two times higher in the group of patients with affective disorders, compared with the group of patients with no psychiatric history (Table 1). However, at the same time, the mortality rate of patients with anxiety disorders did not differ from the control group.

In connection with the data obtained during the research, psychiatrists turned to the analysis of the mutual influence of viral infections and psychopathological disorders, especially in terms of schizophrenia. Their attention was drawn to the historically viral concept of schizophrenia [25], and to the work by Menninger “Influenza and Schizophrenia: Analysis of Post-Influenza Dementia Praecox in 1918 and Five Years Later” [26]. The viral theory of schizophrenia assumed that the key factor in the induction of this pathology is a prenatal viral infection (i.e., retroviruses and viruses of the herpes family) [27, 28].

At a novel stage in the development of psychiatry, it was suggested that influenza has several pathogenic pathways in both the prenatal and postnatal periods, which thereby increased the risk of schizophrenia [29].

However, more current studies have shown that the incidence of a primary psychiatric diagnosis (including schizophrenia) between the week 2 and the month 3 after recovery was 5.8%, and the occurrence of any psychopathological symptoms after COVID-19 was approximately two times more common than was found with influenza or other acute respiratory infections. Thus, the implication was that the new coronavirus infection turned out to be more pathogenic for the psyche than other viral infections.


In this regard, the question arose about the mechanisms of the particular impact of COVID-19 on mentally disabled patients. Behavioral, somatic (comorbid), and pharmacotherapeutic factors were among the groups of factors that worsened the prognosis of the underlying disease during the pandemic. The first group included risky behavior and ignoring the danger of COVID-19, the poor financial situation of patients and the inability to purchase personal protective equipment, the refusal of vaccination, and a delusional interpretation of the pandemic. The second group included diabetes mellitus, obesity, hypertension, and chronic obstructive pulmonary disease, which was registered in patients with mental disorders, and the group 3 included the use of psychopharmacotherapy [30–34].

It has been suggested that the most significant contribution to the development of the severe course of COVID-19 and the mortality of patients with schizophrenia is made by a high level of comorbidity with diseases, in particular hypertension, diabetes mellitus, and chronic obstructive pulmonary disease. It was, therefore, proposed to change the therapeutic approaches to schizophrenia radically [35] due to the significance of the iatrogenic pathway of deterioration in the health of mentally disabled patients.

It is known that many psychotropic drugs can affect somatic health indicators negatively. Thus, for example, carbamazepine, valproates, and several antipsychotics can suppress the activity of myelocytes, increasing hypovolemia and electrolyte disorders; benzodiazepines can cause a decrease in

**Table 2.** Risk of developing diabetes mellitus and weight gain with the use of various antipsychotics [37]

	Risk of weight gain	Risk of diabetes mellitus	D <sub>2</sub> - dopamine	5HT <sub>2c</sub> - serotonin	5HT <sub>1a</sub> - serotonin	M <sub>3</sub> - muscarinic	α <sub>2</sub> - Adrenergic	Hi- histamine
Role in body weight regulation			√	√				√
Role in insulin secretion			√		√	√	√	
First-generation antipsychotics								
Chlorpromazine	+++	+++	++++	++++	+	++++	+	++++
Perphenazine	+	+	++++	++++	+	+	+	+++
Haloperidol	++	+	++++	++	-	+	+	+/-
Second-generation antipsychotics								
Clozapine	+++	+++	+++	+++	++	+++	++	+++
Olanzapine	+++	+++	+	+++	+	+++	+	+++
Quetiapine	++	++	+	+	+	+	+++	++
Risperidone	++	++	+++	++++	++	-	++++	++
Ziprasidone	+	+	+++	++++	++++	-	++	+
Aripiprazole	+	+	++++	+++	++++	-	++	+
Paliperidone	++	+	+++	++++	+	-	+++	++
Lurasidone	+	+	++++	++	++++	-	N/A	-



**Fig. 2.** The risk of becoming overweight when using various antidepressants [41].

muscle tone, increasing myasthenia and inhibiting respiratory function, and thereby increasing the risk of pneumonia; and central anticholinergic drugs (trihexyphenidyl, biperiden, etc.) increase the risk of pneumonia in older patients by between 1.6 and 2.5 times [4].

Such an analysis led to the conclusion that it is necessary to focus on the safety of drugs used in the treatment of patients with schizophrenia, especially on the appropriate use of antipsychotics [36]. The risk

of developing two of the most important factors that aggravate the course and prognosis of COVID-19 (diabetes mellitus and weight gain) is known to vary when different antipsychotics are used (Table 2). The lowest risk was found for ziprasidone, aripiprazole, lurasidone, and paliperidone, and the highest risk was revealed for chlorpromazine, clozapine, and olanzapine [37].

The risk of diabetes mellitus when using antidepressants is not the same either, as it is 1.25 when

using selective serotonin reuptake inhibitors, 1.33 when using other antidepressants, 1.65 when using tricyclic antidepressants, and 1.82 with their combined use [38]. Long-term use of antidepressants increases the risk of type 2 diabetes mellitus in a timing- and dosing-dependent manner [38–40].

A comparative study of the risk assessment of becoming overweight when using antidepressants showed that mirtazapine and citalopram are among the most risky (Fig. 2) [41].

Another paradoxical psychopharmacological fact that emerged during the COVID-19 pandemic was the information that the use of certain antidepressants in those patients without signs of mental disorders can lead to the prevention of severe COVID-19 and reduce the attendant mortality rate. Based on the results of a scientific analysis of 15 randomized clinical trials of some 290,950 patients, this conclusion was found to be proven [38]. Fluvoxamine was among such antidepressants [42]. In addition, psychiatric hospital patients who took antidepressants were found to have a reduced risk of contamination with COVID-19. This led scientists to conclude that antidepressants could be an important weapon in the struggle against COVID-19 [33].

## СПИСОК ИСТОЧНИКОВ

1. Poletti S., Palladini M., Mazza M.G. et al. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: Role of depression and impact on quality of life // *European Archives of Psychiatry and Clinical Neuroscience*. 2022. Vol. 272. N. 5. P. 773–782. DOI: 10.1007/s00406-021-01346-9.
2. Raina P., Wolfson Ch., Griffith L. et al. A longitudinal analysis of the impact of the COVID-19 pandemic on the mental health of middle-aged and older adults from the Canadian Longitudinal Study on Aging // *Nature Aging*. 2021. Vol. 1. P. 1137–1147. DOI: 10.1038/s43587-021-00128-1.
3. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic // *Lancet Psychiatry*. 2021. Vol. 398. P. 1700–1712. DOI: 10.1016/S0140-6736(21)02143-7.
4. Мосолов С.Н. Длительные психические нарушения после перенесённой острой коронавирусной инфекции SARS-CoV-2 // *Современная терапия психических расстройств*. 2021. Т. 3. С. 2–23. DOI: 10.21265/PSYPH.2021.31.25.001.
5. Менделевич В.Д., Муллина Н.Б. Случай острой гипомании при COVID-19: повинен ли коронавирус? // *Психиатрия и психофармакотерапия*. 2020. Т. 22. №5. С. 51–54.
6. Kozato N., Mishra M., Firdosi M. New-onset psychosis due to COVID-19 // *BMJ Case Rep*. 2021. Vol. 14. P. e242538. DOI: 10.1136/bcr-2021-242538.

Thus, what psychiatrists learned from the analysis of findings from the COVID-19 pandemic enables us to draw the following conclusions:

1) Mentally disabled patients represent one of the most vulnerable groups in terms of mortality and complications from COVID-19 and other viral infections

2) It was noted that the use of psychopharmacological agents made a significant contribution to alleviating the negative consequences of COVID-19 in mentally disabled patients

3) Special attention should be paid to the safety criteria of psychopharmacotherapy

4) Some antidepressants are effective in treating COVID-19.

**Финансирование.** Исследование не имело спонсорской поддержки.

**Конфликт интересов.** Авторы заявляют об отсутствии конфликта интересов.

**Вклад авторов.** Менделевич В.Д., Гатин Ф.Ф., Хамитов Р.Р. — анализ литературы.

**Funding.** This publication was not supported by any external sources of funding.

**Conflict of interests.** The authors declare no conflicts of interests.

**Contribution of the authors.** V.D. Mendelevich, F.F. Gatin, R.R. Khamitov — literature analysis.

7. Tariku M., Hajure M. Available evidence and ongoing hypothesis on corona virus (COVID-19) and psychosis: Is corona virus and psychosis related? A narrative review // *Psychology Research and Behavior Management*. 2020. Vol. 13. P. 701–704. DOI: 10.2147/PRBM.S264235.
8. Parra A., Juanes A., Losada C.P. et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study // *Psychiatry Research*. 2020. Vol. 291. P. 113254. DOI: 10.1016/j.psychres.2020.113254.
9. Steardo L.Jr., Steardo L., Verkhatsky A. Psychiatric face of COVID-19 // *Translational Psychiatry*. 2020. Vol. 10. P. 261. DOI: 10.1038/s41398-020-00949-5.
10. Rogers J.P., Chesney E., Oliver D. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic // *Lancet Psychiatry*. 2020. Vol. 7. P. 611–627. DOI: 10.1016/S2215-0366(20)30203-0.
11. Voitsidis P., Gliatas I., Bairachtari V. et al. Insomnia during the COVID-19 pandemic in a Greek population // *Psychiatry Research*. 2020. Vol. 289. P. 113076. DOI: 10.1016/j.psychres.2020.113076.
12. Hartung T.J., Neumann Ch., Bahmer Th. et al. Fatigue and cognitive impairment after COVID-19: A prospective multi-centre study // *eClinicalMedicine* 2022. Vol. 53. P. 101651. DOI: 10.1016/j.eclinm.2022.101651.
13. Houben S., Bonnechère B. The impact of COVID-19 infection on cognitive function and the implication for rehabilitation: A

- systematic review and meta-analysis // *Int. J. Environ. Res. Public Health*. 2022. Vol. 19. P. 7748. DOI: 10.3390/ijerph19137748.
14. Hampshire A., Trender W., Chamberlain S.R. et al. A mehta cognitive deficits in people who have recovered from COVID-19 // *eClinicalMedicine*. 2021. Vol. 39. P. 101044. DOI: 10.1016/j.eclinm.2021.101044.
15. Zhand N., Joobar R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: Narrative review // *BJPsych Open*. 2021. Vol. 7. N. e35. P. 1–7. DOI: 10.1192/bjo.2020.157.
16. Mohan M., Perry B.I., Saravanan P., Singh S.P. COVID-19 in people with schizophrenia: Potential mechanisms linking schizophrenia to poor prognosis // *Front. Psychiatry*. 2021. Vol. 12. P. 666067. DOI: 10.3389/fpsy.2021.666067.
17. Fonseca L., Diniz E., Mendonca G. et al. Schizophrenia and COVID-19: Risks and recommendations // *Braz. J. Psychiatry*. 2020. Vol. 42. N. 3. P. 236–238. DOI: 10.1590/1516-4446-2020-0010.
18. Caqueo-Urizar A., Urzua A., Ponce-Correa F., Ferrer R. Psychosocial effect of the COVID-19 pandemic on patients with schizophrenia and their caregivers // *Frontiers on Psychology*. 2021. Vol. 12. P. 729793. DOI: 10.3389/fpsyg.2021.729793.
19. Taquet M., Sillett R., Zhu L. et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1,284,437 patients // *Lancet Psychiatry*. 2022. Vol. 9. P. 815–827. DOI: 10.1016/S2215-0366(22)00260-7.
20. Bourmistrova N.W., Solomon T., Braude Ph. et al. Long-term effects of COVID-19 on mental health: A systematic review // *J. Affect. Disord*. 2022. Vol. 299. P. 118–125. DOI: 10.1016/j.jad.2021.11.031.
21. Brown E.E., Kumar S., Rajji T.K. et al. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer's disease and related dementias // *Am. J. of Geriatric Psychiatry*. 2020. Vol. 28. N. 7. P. 712–721. DOI: 10.1016/j.jagp.2020.04.010.
22. Fond G., Nemani K., Etchecopar-Etchart D., Loundou A. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries; A systematic review and meta-analysis // *JAMA Psychiatry*. 2021. Vol. 78. N. 11. P. 1208–1217. DOI: 10.1001/jamapsychiatry.2021.2274.
23. Dembosky A. Having schizophrenia is the second biggest risk factor for dying from COVID-19. Connecticut Public. 20 March 2022. <https://www.ctpublic.org/2022-03-20/having-schizophrenia-is-the-second-biggest-risk-factor-for-dying-from-covid-19> (access date: 02.12.2022).
24. Nemani K., Li Ch., Olfson M. et al. Association of psychiatric disorders with mortality among patients with COVID-19 // *JAMA Psychiatry*. 2021. Vol. 78. N. 4. P. 380–386. DOI: 10.1001/jamapsychiatry.2020.4442.
25. Kepinska A.P., Lyegbe C.O., Vermon A.C. et al. Schizophrenia and influenza at the centenary of the 1918–1919 Spanish influenza pandemic: Mechanisms of psychosis risk // *Front. Psychiatry*. 2020. Vol. 11. P. 72. DOI: 10.3389/fpsy.2020.00072.
26. Menninger K.A. Influenza and schizophrenia. An analysis of post-influenzal “dementia precox” as of 1918, and five years later // *The American Journal of Psychiatry*. 2006. Vol. 82. N. 4. P. 469–529. DOI: 10.1176/ajp.82.4.469.
27. Brown A.S., Begg M.D., Gravenstein S. et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia // *Arch. Gen. Psychiat*. 2004. Vol. 61. P. 774–780. DOI: 10.1001/archpsyc.61.8.774.
28. Pearce B.D. Schizophrenia and viral infection during neurodevelopment: A focus on mechanisms // *Mol. Psychiat*. 2001. Vol. 6. P. 634–646. DOI: 10.1038/sj.mp.4000956.
29. Magalhães D., Ferreira F., Ferreira T. et al. Influenza and schizophrenia: How can we shed a light in the new virus from an old association? // *European Psychiatry*. 2021. Vol. 64. P. 168. DOI: 10.1192/j.eurpsy.2021.447.
30. Fusick A.J., Gunther S., Sullivan G. The anti-vaccination movement: When does a belief become delusional? // *Journal of Public Health*. 2021. Vol. 29. P. 1301–1302. DOI: 10.1007/s10389-020-01244-9.
31. Bitan D.T., Kridin K., Cohen A.D., Weinstein O. COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: A longitudinal cohort study // *Lancet Psychiatry*. 2021. Vol. 8. P. 901–908. DOI: 10.1016/S2215-0366(21)00256-X.
32. Bitan D.T. Patients with schizophrenia are under-vaccinated for COVID-19: A report from Israel // *World Psychiatry*. 2020. Vol. 20. N. 2. P. 300–301. DOI: 10.1002/wps.20874.
33. Nakhæe H., Zangiabadian M., Bayati R. et al. The effect of antidepressants on the severity of COVID-19 in hospitalized patients: Systematic review and meta-analysis // *PLoS One*. 2022. Vol. 17. N. 10. P. e0267423. DOI: 10.1371/journal.pone.0267423.
34. Clelland C.L., Ramiah K., Steinberg L., Clelland G.D. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort // *BJPsych. Open*. 2021. Vol. 8. N. 1. P. e6. DOI: 10.1192/bjo.2021.1053.
35. Ekinçi O. Do we need to change our treatment approach to schizophrenia during the COVID-19 pandemic? // *Int. J. Clin. Pract*. 2021. Vol. 75. P. e14013. DOI: 10.1111/ijcp.14013.
36. Pardamean E., Roan W., Amartini Iskandar K.T. et al. Mortality from coronavirus disease 2019 (COVID-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression // *Gen. Hosp. Psychiatry*. 2022. Vol. 75. P. 61–67. DOI: 10.1016/j.genhosppsych.2022.01.010.
37. Holt R.I.G. Association between antipsychotic medication use and diabetes // *Curr. Diab. Rep*. 2019. Vol. 19. N. 10. P. 96. DOI: 10.1007/s11892-019-1220-8.
38. Azevedo da Silva M., Fournier A., Boutron-Ruault M.C. et al. Increased risk of type 2 diabetes in antidepressant users: Evidence from a 6-year longitudinal study in the E3N cohort // *Diabetic Medicine*. 2020. Vol. 37. N. 11. P. 1866–1873. DOI: 10.1111/DME.14345.
39. Wharton S., Raiber L., Serodio K.J. et al. Medications that cause weight gain and alternatives in Canada: A narrative review // *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2018. Vol. 11. P. 427–438. DOI: 10.2147/DMSO.S171365.
40. Miidera H., Enomoto M., Kitamura S. et al. Association between the use of antidepressants and the risk of type 2 diabetes: A large, population-based cohort study in Japan // *Diabetes Care*. 2020. Vol. 43. P. 885–893. DOI: 10.2337/dc19-1175.
41. Gafoor R., Booth H.P., Gulliford M.C. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study // *BMJ*. 2018. Vol. 23. N. 361. P. k1951. DOI: 10.1136/bmj.k1951.
42. Reis G., dos Santos Moreira-Silva E.A., Medeiros Silva D.C. et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial // *Lancet Glob. Health*. 2022. Vol. 10. P. e42–51. DOI: 10.1016/S2214-109X(21)00448-4.

## REFERENCES

- Poletti S, Palladini M, Mazza MG et al. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: Role of depression and impact on quality of life. *European Archives of Psychiatry and Clinical Neuroscience*. 2022;272(5):773–782. DOI: 10.1007/s00406-021-01346-9.
- Raina P, Wolfson Ch, Griffith L et al. A longitudinal analysis of the impact of the COVID-19 pandemic on the mental health of middle-aged and older adults from the Canadian Longitudinal Study on Aging. *Nature Aging*. 2021;1:1137–1147. DOI: 10.1038/s43587-021-00128-1.
- COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet Psychiatry*. 2021;398:1700–1712. DOI: 10.1016/S0140-6736(21)02143-7.
- Mosolov SN. Dlitel'nye psihicheskie narusheniya posle perenesenoi ostroi koronavirusnoi infekcii SARS-CoV-2. *Sovremennaya terapiya psihicheskikh rasstroistv*. 2021;3:2–23. DOI: 10.21265/PSYPH.2021.31.25.001.
- Mendelevich VD, Mullina NB. Sluchaj ostroj gipomanii pri COVID-19: povinen li koronavirus? *Psihiatriya i psihofarmakoterapiya*. 2020;22(5):51–54.
- Kozato N, Mishra M, Firdosi M. New-onset psychosis due to COVID-19. *BMJ Case Rep*. 2021;14:e242538. DOI: 10.1136/bcr-2021-242538.
- Tariku M, Hajure M. Available evidence and ongoing hypothesis on corona virus (COVID-19) and psychosis: Is corona virus and psychosis related? A narrative review. *Psychology Research and Behavior Management*. 2020;13:701–704. DOI: 10.2147/PRBM.S264235.
- Parra A, Juanes A, Losada CP et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. *Psychiatry Research*. 2020;291:113254. DOI: 10.1016/j.psychres.2020.113254.
- Stearo LJr, Steardo L, Verkhatsky A. Psychiatric face of COVID-19. *Translational Psychiatry*. 2020;10:261. DOI: 10.1038/s41398-020-00949-5.
- Rogers JP, Chesney E, Oliver D et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry*. 2020;7:611–627. DOI: 10.1016/S2215-0366(20)30203-0.
- Voitsidis P, Gliatas I, Bairachtari V et al. Insomnia during the COVID-19 pandemic in a Greek population. *Psychiatry Research*. 2020;289:113076. DOI: 10.1016/j.psychres.2020.113076.
- Hartung TJ, Neumann Ch, Bahmer Th et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. *eClinicalMedicine*. 2022;53:101651. DOI: 10.1016/j.eclinm.2022.101651.
- Houben S, Bonnechère B. The impact of COVID-19 infection on cognitive function and the implication for rehabilitation: A systematic review and meta-analysis. *Int J Environ Res Public Health*. 2022;19:7748. DOI: 10.3390/ijerph19137748.
- Hampshire A, Trender W, Chamberlain SR et al. A mehta cognitive deficits in people who have recovered from COVID-19. *eClinicalMedicine*. 2021;39:101044. DOI: 10.1016/j.eclinm.2021.101044.
- Zhand N, Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: Narrative review. *BJPsych Open*. 2021;7(e35):1–7. DOI: 10.1192/bjo.2020.157.
- Mohan M, Perry BI, Saravanan P, Singh SP. COVID-19 in people with schizophrenia: Potential mechanisms linking schizophrenia to poor prognosis. *Front Psychiatry*. 2021;12:666067. DOI: 10.3389/fpsy.2021.666067.
- Fonseca L, Diniz E, Mendonca G et al. Schizophrenia and COVID-19: Risks and recommendations. *Braz J Psychiatry*. 2020;42(3):236–238. DOI: 10.1590/1516-4446-2020-0010.
- Caqueo-Urizar A, Urzua A, Ponce-Correa F, Ferrer R. Psychosocial effect of the COVID-19 pandemic on patients with schizophrenia and their caregivers. *Frontiers on Psychology*. 2021;12:729793. DOI: 10.3389/fpsyg.2021.729793.
- Taquet M, Sillett R, Zhu L et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1,284,437 patients. *Lancet Psychiatry*. 2022;9:815–827. DOI: 10.1016/S2215-0366(22)00260-7.
- Bourmistrova NW, Solomon T, Braude Ph et al. Long-term effects of COVID-19 on mental health: A systematic review. *J Affect Disord*. 2022;299:118–125. DOI: 10.1016/j.jad.2021.11.031.
- Brown EE, Kumar S, Rajji TK et al. Anticipating and mitigating the impact of the COVID-19 pandemic on Alzheimer's disease and related dementias. *Am J Geriatric Psychiatry*. 2020;28(7):712–721. DOI: 10.1016/j.jagp.2020.04.010.
- Fond G, Nemani K, Etcheopar-Etchart D, Loundou A. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries; A systematic review and meta-analysis. *JAMA Psychiatry*. 2021;78(11):1208–1217. DOI: 10.1001/jamapsychiatry.2021.2274.
- Dembosky A. *Having schizophrenia is the second biggest risk factor for dying from COVID-19*. Connecticut Public. 20 March 2022. <https://www.ctpublic.org/2022-03-20/having-schizophrenia-is-the-second-biggest-risk-factor-for-dying-from-covid-19> (access date: 02.12.2022).
- Nemani K, Li Ch, Olfson M et al. Association of psychiatric disorders with mortality among patients with COVID-19. *JAMA Psychiatry*. 2021;78(4):380–386. DOI: 10.1001/jamapsychiatry.2020.4442.
- Kepinska AP, Lyegbe CO, Vermon AC et al. Schizophrenia and influenza at the centenary of the 1918–1919 Spanish influenza pandemic: Mechanisms of psychosis risk. *Front Psychiatry*. 2020;11:72. DOI: 10.3389/fpsy.2020.00072.
- Menninger KA. Influenza and schizophrenia. An analysis of post-influenzal “dementia precox” as of 1918, and five years later. *The American Journal of Psychiatry*. 2006;82(4):469–529. DOI: 10.1176/ajp.82.4.469.
- Brown AS, Begg MD, Gravenstein S et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. *Arch Gen Psychiat*. 2004;61:774–780. DOI: 10.1001/archpsyc.61.8.774.
- Pearce BD. Schizophrenia and viral infection during neurodevelopment: A focus on mechanisms. *Mol Psychiat*. 2001;6:634–646. DOI: 10.1038/sj.mp.4000956.
- Magalhães D, Ferreira F, Ferreira T et al. Influenza and schizophrenia: How can we shed a light in the new virus from an old association? *European Psychiatry*. 2021;64:168. DOI: 10.1192/j.eurpsy.2021.447.
- Fusick AJ, Gunther S, Sullivan G. The anti-vaccination movement: when does a belief become delusional? *Journal of Public Health*. 2021;29:1301–1302. DOI: 10.1007/s10389-020-01244-9.
- Bitan DT, Kridin K, Cohen AD, Weinstein O. COVID-19



hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: A longitudinal cohort study. *Lancet Psychiatry*. 2021;8:901–908. DOI: 10.1016/S2215-0366(21)00256-X.

32. Bitan DT. Patients with schizophrenia are under-vaccinated for COVID-19: A report from Israel. *World Psychiatry*. 2020;20(2):300–301. DOI: 10.1002/wps.20874.

33. Nakhaee H, Zangiabadian M, Bayati R et al. The effect of antidepressants on the severity of COVID-19 in hospitalized patients: Systematic review and meta-analysis. *PLoS One*. 2022;17(10):e0267423. DOI: 10.1371/journal.pone.0267423.

34. Clelland CL, Ramiah K, Steinberg L, Clelland GD. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. *BJPsych Open*. 2021;8(1):e6. DOI: 10.1192/bjo.2021.1053.

35. Ekinci O. Do we need to change our treatment approach to schizophrenia during the COVID-19 pandemic? *Int J Clin Pract*. 2021;75:e14013. DOI: 10.1111/ijcp.14013.

36. Pardamean E, Roan W, Amartini Iskandar KT et al. Mortality from coronavirus disease 2019 (COVID-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression. *Gen Hosp Psychiatry*. 2022;75:61–67. DOI: 10.1016/j.genhosppsy.2022.01.010.

37. Holt RIG. Association between antipsychotic medication use

and diabetes. *Curr Diab Rep*. 2019;19(10):96. DOI: 10.1007/s11892-019-1220-8.

38. Azevedo da Silva M, Fournier A, Boutron-Ruault MC et al. Increased risk of type 2 diabetes in antidepressant users: evidence from a 6-year longitudinal study in the E3N cohort. *Diabetic Medicine*. 2020;37(11):1866–1873. DOI: 10.1111/DME.14345.

39. Wharton S, Raiber L, Serodio KJ et al. Medications that cause weight gain and alternatives in Canada: A narrative review. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2018;11:427–438. DOI: 10.2147/DMSO.S171365.

40. Miidera H, Enomoto M, Kitamura S et al. Association between the use of antidepressants and the risk of type 2 diabetes: A large, population-based cohort study in Japan. *Diabetes Care*. 2020;43:885–893. DOI: 10.2337/dc19-1175.

41. Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. *BMJ*. 2018;23(361):k1951. DOI: 10.1136/bmj.k1951.

42. Reis G, dos Santos Moreira-Silva EA, Medeiros Silva DC et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial. *Lancet Glob Health*. 2022;10:e42–51. DOI: 10.1016/S2214-109X(21)00448-4.

## ОБ АВТОРАХ

**Менделевич Владимир Давыдович**, докт. мед. наук, проф., зав. каф., каф. психиатрии и медицинской психологии; ORCID: <http://orcid.org/0000-0002-8476-6083>; eLibrary SPIN: 2302-2590; e-mail: [mendelevich\\_vl@mail.ru](mailto:mendelevich_vl@mail.ru)

**Гатин Фоат Фатыхович**, докт. мед. наук, проф., зав. каф., каф. психиатрии и судебно-психиатрической экспертизы; ORCID: <http://orcid.org/0000-0001-9528-8833>; eLibrary SPIN: 1567-9265; e-mail: [bagautdinowa.lejsan@yandex.ru](mailto:bagautdinowa.lejsan@yandex.ru)

**Хамитов Рустем Радикович**, докт. мед. наук, проф., каф. психиатрии и медицинской психологии; ORCID: <http://orcid.org/0000-0002-1271-8330>; eLibrary SPIN: 4923-9370; e-mail: [psycheya.kzn@mail.ru](mailto:psycheya.kzn@mail.ru)

## AUTHOR'S INFO

**Vladimir D. Mendelevich**, M.D., D. Sci. (Med.), Prof., Head of the Depart., Depart. of Psychiatry and Medical Psychology; ORCID: <http://orcid.org/0000-0002-8476-6083>; eLibrary SPIN: 2302-2590; e-mail: [mendelevich\\_vl@mail.ru](mailto:mendelevich_vl@mail.ru)

**Foat F. Gatin**, M.D., D. Sci. (Med.), Prof., Head of the Depart., Depart. of Psychiatry and Forensic Psychiatric Examination; ORCID: <http://orcid.org/0000-0001-9528-8833>; eLibrary SPIN: 1567-9265; e-mail: [bagautdinowa.lejsan@yandex.ru](mailto:bagautdinowa.lejsan@yandex.ru)

**Rustem R. Khamitov**, M.D., D. Sci. (Med.), Prof., Depart. of Psychiatry and Medical Psychology; ORCID: <http://orcid.org/0000-0002-1271-8330>; eLibrary SPIN: 4923-9370; e-mail: [psycheya.kzn@mail.ru](mailto:psycheya.kzn@mail.ru)